-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 1, the CDE official website showed that the clinical trial application of Johnson & Johnson's BCMA/CD3 bispecific antibody Teclistamab injection (acceptance number: JXSL2101002/3) was accepted by the CDE.
Teclistamab is a bispecific antibody developed using Genmab DuoBody® technology that can simultaneously target T cell CD3 and multiple myeloma (MM) cell BCMA.
In December 2020, Johnson & Johnson announced the data of the first human phase I clinical study of teclistamab (NCT03145181), which evaluated the efficacy of teclistamab in the treatment of patients with relapsed or refractory multiple myeloma (MM).
research shows.
Domestic companies that have deployed BCMA/CD3 bispecific antibody therapy include Amgen (AMG 701) and Shandong New Era.